Sinovac Biotech, Ltd (SVA) Posts Q2 Loss of 4c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts SVA Hot Sheet
Join SI Premium – FREE
Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q2 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.1 million versus the consensus estimate of $17.2 million.
For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Nomura/Instinet Downgrades LG Chem Ltd (051910:KS) (LGCLF) to Neutral
- Baird Upgrades Humana (HUM) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
